Solid phase synthesis and some hormonal activities of 1-deamino-4-L-valine-8-D-homolysine-and 1-deamino-4-L-valine-8-D-homoarginine-vasopressin.
1-Deamino-4-L-valine-8-DL-homolysine-vasopressin and protected 1-deamino-4-l-valine-8-D-lysine-vasopressin were synthesized by the solid phase method and were then converted into the title compounds (dVDHLVP and dVDHAVP) by tryptic digestion and epsilon-guanidination, respectively. The new hormone analogues exhibit only moderate antidiuretic potency, dVDHLVP 21 units/mg and dVDHAVP 31 units/mg, but since they are essentially devoid of pressor activity (o.o1 units/mg/ the A/P ratios are very high. In fact, dVDHLVP is the most specific antidiuretic agent in the lysine series known so far.
D000595:Amino Acid Sequence; D000818:Animals; D004231:Diuresis / Q000187:drug effects; D008297:Male; D010455:Peptides / Q000138:chemical synthesis*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D014667:Vasopressins / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology
D010455:Peptides; D014667:Vasopressins